WA
VRTX icon

WESPAC Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

WESPAC Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-670
Closed -$280K – 184
2024
Q1 		$280K Hold
670
– – 0.16% 145
2023
Q4 		$273K Hold
670
– – 0.19% 124
2023
Q3 		$233K Buy
+670
New +$234K 0.17% 125
2019
Q2 		– Sell
-3,361
Closed -$618K – 144
2019
Q1 		$618K Buy
+3,361
New +$621K 0.43% 68
2018
Q4 		– Sell
-1,319
Closed -$254K – 165
2018
Q3 		$254K Buy
+1,319
New +$235K 0.15% 124
2018
Q2 		– Sell
-5,321
Closed -$867K – 148
2018
Q1 		$867K Buy
+5,321
New +$869K 0.53% 60

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

WESPAC Advisors's VRTX Position: Q2 2024 in Review

WESPAC Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 670 shares — an estimated $280K sold.

WESPAC Advisors first reported a position in VRTX in Q1 2018 and held it in 6 quarters. The position peaked at $867K in Q1 2018. 1,549 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • WESPAC Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • WESPAC Advisors sold 670 Vertex Pharmaceuticals shares in Q2 2024, an estimated $280K.
  • WESPAC Advisors first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 6 quarters.
  • WESPAC Advisors's Vertex Pharmaceuticals position peaked at $867K in Q1 2018.
  • 1,549 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on WESPAC Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.